MARKET

HRTX

HRTX

Heron Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.60
-0.80
-3.42%
After Hours: 22.75 +0.15 +0.66% 16:39 01/24 EST
OPEN
23.40
PREV CLOSE
23.40
HIGH
23.83
LOW
22.24
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
28.70
52 WEEK LOW
15.68
MARKET CAP
2.00B
P/E (TTM)
-9.0785
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of HRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

HRTX News

  • Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8%
  • Zacks.4d ago
  • Heron Therapeutics Highlights Progress In Pain Management And CINV Franchises
  • Benzinga.01/13 13:37
  • Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
  • PR Newswire.01/13 13:30
  • Biotech's Most Volatile Binary Events for Q1
  • MotleyFool.com.01/03 12:00

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About HRTX

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
More

Webull offers Heron Therapeutics Inc (HRTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.